CN1151151C - 8-甲氧基-喹诺酮羧酸类的制备方法 - Google Patents

8-甲氧基-喹诺酮羧酸类的制备方法

Info

Publication number
CN1151151C
CN1151151C CNB988114445A CN98811444A CN1151151C CN 1151151 C CN1151151 C CN 1151151C CN B988114445 A CNB988114445 A CN B988114445A CN 98811444 A CN98811444 A CN 98811444A CN 1151151 C CN1151151 C CN 1151151C
Authority
CN
China
Prior art keywords
process according
solvent
equivalents
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988114445A
Other languages
English (en)
Chinese (zh)
Other versions
CN1279683A (zh
Inventor
R�����ָ�
R·格林格
K·莫尔斯
W·海尔曼
H·迪尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CN1279683A publication Critical patent/CN1279683A/zh
Application granted granted Critical
Publication of CN1151151C publication Critical patent/CN1151151C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNB988114445A 1997-11-24 1998-11-12 8-甲氧基-喹诺酮羧酸类的制备方法 Expired - Lifetime CN1151151C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19751948A DE19751948A1 (de) 1997-11-24 1997-11-24 Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
DE19751948.2 1997-11-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB021319626A Division CN1200938C (zh) 1997-11-24 2002-09-04 8－甲氧基－喹诺酮羧酸类的制备方法

Publications (2)

Publication Number Publication Date
CN1279683A CN1279683A (zh) 2001-01-10
CN1151151C true CN1151151C (zh) 2004-05-26

Family

ID=7849617

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988114445A Expired - Lifetime CN1151151C (zh) 1997-11-24 1998-11-12 8-甲氧基-喹诺酮羧酸类的制备方法
CNB021319626A Expired - Lifetime CN1200938C (zh) 1997-11-24 2002-09-04 8－甲氧基－喹诺酮羧酸类的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021319626A Expired - Lifetime CN1200938C (zh) 1997-11-24 2002-09-04 8－甲氧基－喹诺酮羧酸类的制备方法

Country Status (40)

Country Link
US (2) US6897315B2 (cg-RX-API-DMAC10.html)
EP (1) EP1034173B1 (cg-RX-API-DMAC10.html)
JP (1) JP4445667B2 (cg-RX-API-DMAC10.html)
KR (1) KR100589549B1 (cg-RX-API-DMAC10.html)
CN (2) CN1151151C (cg-RX-API-DMAC10.html)
AR (1) AR016694A1 (cg-RX-API-DMAC10.html)
AT (1) ATE294169T1 (cg-RX-API-DMAC10.html)
AU (1) AU732977B2 (cg-RX-API-DMAC10.html)
BG (1) BG64532B1 (cg-RX-API-DMAC10.html)
BR (1) BRPI9814894B8 (cg-RX-API-DMAC10.html)
CA (2) CA2711645C (cg-RX-API-DMAC10.html)
CO (1) CO5011069A1 (cg-RX-API-DMAC10.html)
CU (1) CU22953A3 (cg-RX-API-DMAC10.html)
CZ (1) CZ297212B6 (cg-RX-API-DMAC10.html)
DE (2) DE19751948A1 (cg-RX-API-DMAC10.html)
DK (1) DK1034173T3 (cg-RX-API-DMAC10.html)
EE (1) EE04281B1 (cg-RX-API-DMAC10.html)
ES (1) ES2241185T3 (cg-RX-API-DMAC10.html)
HN (1) HN1998000179A (cg-RX-API-DMAC10.html)
HR (1) HRP20000332B1 (cg-RX-API-DMAC10.html)
HU (1) HU228337B1 (cg-RX-API-DMAC10.html)
ID (1) ID26840A (cg-RX-API-DMAC10.html)
IL (1) IL135866A0 (cg-RX-API-DMAC10.html)
IN (1) IN189753B (cg-RX-API-DMAC10.html)
MY (1) MY129324A (cg-RX-API-DMAC10.html)
NO (1) NO315748B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ504657A (cg-RX-API-DMAC10.html)
PE (1) PE20000007A1 (cg-RX-API-DMAC10.html)
PL (1) PL192461B1 (cg-RX-API-DMAC10.html)
PT (1) PT1034173E (cg-RX-API-DMAC10.html)
RU (1) RU2219175C2 (cg-RX-API-DMAC10.html)
SI (1) SI1034173T1 (cg-RX-API-DMAC10.html)
SK (1) SK285492B6 (cg-RX-API-DMAC10.html)
SV (1) SV1998000139A (cg-RX-API-DMAC10.html)
TR (1) TR200001472T2 (cg-RX-API-DMAC10.html)
TW (1) TW513427B (cg-RX-API-DMAC10.html)
UA (1) UA56286C2 (cg-RX-API-DMAC10.html)
UY (1) UY25265A1 (cg-RX-API-DMAC10.html)
WO (1) WO1999026940A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA9810669B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102030751A (zh) * 2010-12-01 2011-04-27 上虞京新药业有限公司 一种盐酸莫西沙星的结晶工艺

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6664267B1 (en) 2002-05-28 2003-12-16 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
ES2332367T5 (es) * 2003-04-09 2013-12-17 Dr. Reddy's Laboratories Ltd. Forma cristalina III de clorhidrato de moxifloxacina anhidro y su procedimiento de preparación
WO2005012285A1 (en) * 2003-08-05 2005-02-10 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
AU2003304460A1 (en) 2003-09-04 2005-03-29 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
ITMI20032259A1 (it) * 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
US7759362B2 (en) * 2004-04-21 2010-07-20 Institut Of Medicinal Biotechnology Chinese Academy Of Medical Sciences Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof
WO2006134491A2 (en) * 2005-06-14 2006-12-21 Aurobindo Pharma Limited New crystalline form of moxifloxacin hydrochloride and process for its preparation
ES2311391B1 (es) * 2007-02-07 2009-12-22 Quimica Sintetica, S.A. Forma cristalina de moxifloxacino base.
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
IT1398952B1 (it) * 2010-03-19 2013-03-28 F S I Fabbrica Italiana Sint Processo di preparazione della moxifloxacina e suoi sali
CN104370906A (zh) * 2014-11-17 2015-02-25 安徽美诺华药物化学有限公司 氟喹诺酮衍生物的制备方法
CN104370907A (zh) * 2014-11-17 2015-02-25 安徽美诺华药物化学有限公司 喹诺酮衍生物的制备方法
CN104447742A (zh) * 2014-11-17 2015-03-25 安徽美诺华药物化学有限公司 一种喹诺酮衍生物的制备方法
CN104447741A (zh) * 2014-11-17 2015-03-25 安徽美诺华药物化学有限公司 一种氟喹诺酮衍生物的制备方法
CN111771895B (zh) * 2020-08-03 2025-04-25 广西田园生化股份有限公司 喹诺酮类化合物在防治植物细菌性病害柑橘溃疡病上的新用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT77267B (en) * 1982-09-07 1986-03-21 Lilly Co Eli Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto
IE55898B1 (en) * 1982-09-09 1991-02-14 Warner Lambert Co Antibacterial agents
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
JPS62205060A (ja) * 1986-03-04 1987-09-09 Kyorin Pharmaceut Co Ltd ８位置換キノロンカルボン酸誘導体
DK164287A (da) * 1986-03-31 1987-10-01 Sankyo Co Quinolin-3-carboxylsyrederivater og fremgangsmaade til fremstilling deraf og deres anvendelse
HU200175B (en) * 1987-06-24 1990-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing quinolinecarboxylic acid derivatives
EP0342675B1 (en) * 1988-05-19 1995-01-25 Chugai Seiyaku Kabushiki Kaisha Novel quinolonecarboxylic acid derivatives
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
CA1336090C (en) 1988-08-31 1995-06-27 Isao Hayakawa Spiro-substituted cyclic amines of quinolone derivatives
AU4638889A (en) 1988-12-09 1990-06-26 Dainippon Pharmaceutical Co. Ltd. Quinolonecarboxylic acid derivatives, process for their preparation and medicinal composition containing same
JP2761566B2 (ja) 1989-03-10 1998-06-04 吉富製薬株式会社 ピリドンカルボン酸化合物
WO1992009579A1 (fr) 1990-11-30 1992-06-11 Yoshitomi Pharmaceutical Industries, Ltd. Compose d'acide quinolonecarboxylique et son utilisation
JPH05117238A (ja) 1991-10-23 1993-05-14 Chugai Pharmaceut Co Ltd キノロンカルボン酸誘導体の製造方法及びその合成中間体
TW209865B (cg-RX-API-DMAC10.html) 1992-01-10 1993-07-21 Bayer Ag
WO1993022308A1 (fr) 1992-04-28 1993-11-11 Chugai Seiyaku Kabushiki Kaisha Procede pour produire un derive d'acide quinolonecarboxylique
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
DE4230804A1 (de) 1992-09-15 1994-03-17 Bayer Ag 7-Isoindolinyl-chinolon- und -naphthyridon-Derivate
DE4232172A1 (de) 1992-09-25 1994-03-31 Bayer Ag 7-(Aminomethyl-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)chinolon- und Naphthyridoncarbonsäure-Derivate
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
DE4234330A1 (de) * 1992-10-12 1994-04-14 Bayer Ag Chinoloncarbonsäuren
WO1994014794A1 (fr) * 1992-12-28 1994-07-07 Yoshitomi Pharmaceutical Industries, Ltd. Derive d'acide 8-methoxyquinolonecarboxylique
CA2114981A1 (en) * 1993-02-09 1994-08-10 Kazumi Ogata Quinolonecarboxylic acid derivatives
WO1994025464A1 (en) * 1993-04-24 1994-11-10 Korea Research Institute Of Chemical Technology Novel quinolone carboxylic acid derivatives and process for preparing the same
US5631266A (en) * 1993-04-26 1997-05-20 Korea Research Institute Of Chemical Technology Quinolone carboxylic acid derivatives and process for preparing the same
KR950018003A (ko) * 1993-12-09 1995-07-22 스미스클라인 비참 피엘씨 신규한 퀴놀론 유도체 및 그의 제조 방법
GB2289674A (en) 1994-05-23 1995-11-29 Pfizer Antibacterial naphthyridine
DE4435479A1 (de) 1994-10-04 1996-04-11 Bayer Ag Chinolon- und Naphthyridoncarbonsäure-Derivate
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU713704B2 (en) * 1996-01-31 1999-12-09 Sankyo Company Limited Agents for the treatment and prevention of aids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102030751A (zh) * 2010-12-01 2011-04-27 上虞京新药业有限公司 一种盐酸莫西沙星的结晶工艺
CN102030751B (zh) * 2010-12-01 2012-11-21 上虞京新药业有限公司 一种盐酸莫西沙星的结晶工艺

Also Published As

Publication number Publication date
US7115744B2 (en) 2006-10-03
EE04281B1 (et) 2004-04-15
HU228337B1 (en) 2013-03-28
SK285492B6 (sk) 2007-02-01
US20050209276A1 (en) 2005-09-22
BRPI9814894A (pt) 2000-10-03
EP1034173A2 (de) 2000-09-13
IN189753B (cg-RX-API-DMAC10.html) 2003-04-19
MY129324A (en) 2007-03-30
DK1034173T3 (da) 2005-07-25
CN1200938C (zh) 2005-05-11
SV1998000139A (es) 1999-04-13
EE200000241A (et) 2001-06-15
AU732977B2 (en) 2001-05-03
BRPI9814894B1 (pt) 2011-10-18
HRP20000332B1 (hr) 2009-01-31
SK7482000A3 (en) 2000-10-09
NZ504657A (en) 2001-04-27
ID26840A (id) 2001-02-15
PL192461B1 (pl) 2006-10-31
DE19751948A1 (de) 1999-05-27
CO5011069A1 (es) 2001-02-28
KR100589549B1 (ko) 2006-06-14
HK1056169A1 (en) 2004-02-06
CZ297212B6 (cs) 2006-10-11
PT1034173E (pt) 2005-08-31
HK1034080A1 (en) 2001-10-12
CZ20001926A3 (cs) 2000-11-15
BG64532B1 (bg) 2005-06-30
ZA9810669B (en) 1999-05-26
IL135866A0 (en) 2001-05-20
TR200001472T2 (tr) 2002-06-21
PL341088A1 (en) 2001-03-26
US6897315B2 (en) 2005-05-24
RU2219175C2 (ru) 2003-12-20
NO20002637D0 (no) 2000-05-23
HUP0004337A3 (en) 2004-07-28
CA2311540A1 (en) 1999-06-03
WO1999026940A2 (de) 1999-06-03
JP2001524477A (ja) 2001-12-04
EP1034173B1 (de) 2005-04-27
ATE294169T1 (de) 2005-05-15
NO315748B1 (no) 2003-10-20
HUP0004337A2 (hu) 2001-10-28
UY25265A1 (es) 1999-07-19
WO1999026940A3 (de) 1999-08-12
UA56286C2 (uk) 2003-05-15
HN1998000179A (es) 1999-02-09
HRP20000332A2 (en) 2001-04-30
CA2711645C (en) 2016-04-26
BRPI9814894B8 (pt) 2021-07-06
PE20000007A1 (es) 2000-03-05
CN1418879A (zh) 2003-05-21
CA2711645A1 (en) 1999-06-03
CA2311540C (en) 2011-06-14
DE59812758D1 (de) 2005-06-02
SI1034173T1 (en) 2005-10-31
ES2241185T3 (es) 2005-10-16
KR20010032361A (ko) 2001-04-16
CU22953A3 (es) 2004-06-21
TW513427B (en) 2002-12-11
CN1279683A (zh) 2001-01-10
NO20002637L (no) 2000-05-23
AR016694A1 (es) 2001-07-25
AU1561999A (en) 1999-06-15
BG104467A (en) 2001-08-31
JP4445667B2 (ja) 2010-04-07
US20030208069A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
CN1151151C (zh) 8-甲氧基-喹诺酮羧酸类的制备方法
CN1024194C (zh) 喹啉羧酸衍生物的制备方法
CN87100580A (zh) 选择毒性极好的8-烷氧基-4-喹啉羧酸及其盐类和它们的制备方法
CN1753874A (zh) 可用作肾上腺素受体激动剂的 5－′( r )－2－( 5 , 6－二乙基－茚满－2－基氨基)－1－羟基－乙基－8－羟基－(1h)－喹啉－2－酮盐的制备方法
CN87101731A (zh) 8号位上取代的喹诺酮羧酸衍生物及其制备方法
CN1109877A (zh) 一锅法制备3-喹诺酮羧酸衍生物的方法
CN1771234A (zh) 吡咯并三嗪激酶抑制剂的制备方法
CN1436176A (zh) 4－烷氧基－环己烷－1－氨基－羧酸酯及其生产方法
CN1558906A (zh) 嘧啶酮化合物及其药学上可接受的盐的制备方法
CN1043042C (zh) 7－[2－(2－氨基噻唑－4－基)－2－(Z)－羟亚胺基－乙酰胺基]－3－(甲氧甲基)－3－头孢烯－4－羧酸－α－(2,2－二甲基丙酰氧)乙酯拆分的方法
CN1052864A (zh) 喹诺酮化合物及其制备方法
CN1255387C (zh) 可用作选择性cox－2抑制剂的嘧啶衍生物
CN1067656A (zh) 氨甲基取代的2，3-二氢吡喃并[2，3-b]吡啶类，制备方法和在医药中的应用
CN1743308A (zh) 甲砜霉素和氟苯尼考的新合成方法及其关键中间体
CN1227252C (zh) 制备6－甲基－2－(4－甲基－苯基)－咪唑并[1,2－a]吡啶－3－(N,N－二甲基－乙酰胺)和中间体的方法
CN1606557A (zh) 经氘代的吡唑嘧啶酮以及包含该化合物的药物组合物
CN1176921C (zh) 8-氰基-1-环丙基-7-(1s,6s-2,8-二氮杂双环(4.3.0)壬-8-基)-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸的半盐酸盐
CN1563004A (zh) 喹诺酮羧酸类化合物及其制备方法和医药用途
CN100343240C (zh) 手性2－甲基－4－保护的哌嗪的立体选择性烷基化
HK1034080B (en) Method for producing 8-methoxy-quinoline carboxylic acids
HK1056169B (en) Method for producing 8-methoxy-quinolone carboxylic acids
CN1198821C (zh) 磺酰胺衍生物的制备方法及其晶体
CN1256328C (zh) 具有抗菌活性的7位取代胺甲基氟喹诺酮衍生物及制备方法
CN1660798A (zh) 制备氨基苯磺酰脲的方法，及其制备用中间体
CN1090185C (zh) 有双环氨基取代的吡啶酮羧酸衍生物,其酯及盐,以及可用作其中间体的双环类胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BAYER HEALTHCARE AG

Free format text: FORMER OWNER: BAYER AG

Effective date: 20041022

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20041022

Address after: Germany Leverkusen

Patentee after: BAYER HEALTHCARE AG

Address before: Germany Leverkusen

Patentee before: Bayer AG

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1034080

Country of ref document: HK

CI01 Publication of corrected invention patent application

Correction item: 10., the transfer of the patent holder

Correct: Bayer Healthcare AG

False: Bayer Healthcare AG

Number: 48

Page: 628

Volume: 20

ERR Gazette correction

Free format text: CORRECT: 10. PATENTEE TRANSFER; FROM: BAYER HEALTHCARE AG TO: BAYER HEALTHCARE AG

ASS Succession or assignment of patent right

Owner name: BAYER SCHERING PHARMA AG

Free format text: FORMER OWNER: BAYER HEALTHCARE AG

Effective date: 20091127

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091127

Address after: Berlin

Patentee after: Bayer Schering Pharma AG

Address before: Germany Leverkusen

Patentee before: Bayer Healthcare AG

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20130327

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: BAYER PHARMACEUTICALS AG

Free format text: FORMER NAME: BAYER SCHERING PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: Berlin

Patentee after: BAYER PHARMA AG

Address before: Berlin

Patentee before: Bayer Schering Pharma AG

TR01 Transfer of patent right

Effective date of registration: 20130327

Address after: German Monheim

Patentee after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Berlin

Patentee before: BAYER PHARMA AG

CX01 Expiry of patent term

Granted publication date: 20040526

CX01 Expiry of patent term